Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $463.38M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 1.39M
Average 0.69M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +15.3% | -8.3% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +15.3% over three years. Forward estimates point to Revenue at -8.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Iovance Biotherapeutics, Inc. NASDAQ:IOVA | $3.59B | $7.76 | Not rated | -4.6 | +223.45% |
SELLAS Life Sciences Group, Inc. NASDAQ:SLS | $1.59B | $7.86 | Not rated | -47.3 | +877.63% |
Crescent Biopharma, Inc. NASDAQ:CBIO | $525.59M | $14.15 | Not rated | -3.3 | -0.92% |
Puma Biotechnology, Inc. NASDAQ:PBYI | $401.70M | $7.77 | Overvalued | 15.4 | +45.60% |
Indaptus Therapeutics, Inc. NASDAQ:INDP | $358.98M | $3.17 | Not rated | -0.2 | +51.21% |
Faeth Therapeutics, Inc. NASDAQ:FTH | $258.56M | $10.03 | Not rated | -0.2 | -13.27% |
Black Diamond Therapeutics, Inc. NASDAQ:BDTX | $84.48M | $1.47 | Overvalued | -2.2 | -64.27% |
PDS Biotechnology Corporation NASDAQ:PDSB | $48.70M | $0.87 | Not rated | -1.5 | +23.21% |
NovaBridge Biosciences NASDAQ:NBP | $42.59M | $0.85 | Not rated | -25.5 | -80.58% |
Continue the stock analysis
Jump to another research area for this company.